Citations

Clear

585 citation(s) found for "Tran, T".

PD-1 mediates paralysis of ovarian cancer-infiltrating dendritic cells through SHP-2 dependent and independent NFkB inactivation (TUM3P.1048)
Karyampudi, Lavakumar, Lamichhane, Purushottam , Kalli, Kimberly R., Behrens, Marshall D., Vargas, Doris M., Hartmann, Lynn C., Janco, Jo Marie Tran, Goode, Ellen L. , Knutson, Keith L. , Krempski, James , Hedin, Karen E. , Dietz, Allan B. , Knutson, Keith L.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 194 | Issue: 1_Supplement | Pages: 70.5-70.5

10.4049/jimmunol.194.supp.70.5 Get It

Abstract The PD-1:PD-L1 axis is a major immune regulatory pathway that blunts T cell activation in the tumor microenvironment. We recently identified that PD-1 is also upregulated on ovarian mouse tumor-infiltrating myeloid dendritic cells (TIDCs) that exhibit an immune suppressive phenotype. Extending those observations in this study, we now report that PD-1 is also expressed on human myeloid TIDCs of ovarian cancer patients, on which it suppresses the expression of co-stimulatory molecules (CD40 and CD80) as well as production of inflammatory cytokines. Mechanistic studies revealed that PD-1 on TIDCs is associated with Src homology domain-containing phosphatase-2 (SHP-2) and that PD-1-mediated blockade of NFkB-dependent cytokine release is SHP-2 dependent. PD-1 also inhibits NFkB-mediated antigen presentation which appears, however, to be independent of SHP-2. Thus, suppression of NFkB is critical in mediating PD-1-induced paralysis of ovarian tumor-associated immune TIDCs and is mediated through multiple signaling circuits that are both SHP-2 dependent and independent.
TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
Sharplin, Kirsty, Chhetri, Rakchha , Ladon, Dariusz, Al‐Kali, Aref , Litzow, Mark R. , Mangaonkar, Abhishek A. , Gangat, Naseema , Patnaik, Mrinal M. , Begna, Kebede, Tefferi, Ayalew , Shah, Meera , Hahn, Christopher N , Tran, Elizabeth Ngoc Hoa , Baranwal, Anmol , Kutyna, Monika , Wang, Paul Po-Shen , Alkhateeb, Hassan B. , Ross, David M , Yeung, David , Shanmuganathan, Naranie , Hogan, William J. , Kumar, Sharad , Singhal, Deepak , Brown, Anna , Scott, Hamish S. , THOMAS, DANIEL W. , Kok, Chung Hoow , Hiwase, Devendra

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859 Get It

Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
Shultz, Carl , Al‐Kali, Aref , Chhetri, Rakchha , Arsana, Arini, Stish, Bradley J. , Tefferi, Ayalew , Patnaik, Mrinal M. , Gangat, Naseema , Baranwal, Anmol , Tran, Elizabeth Ngoc Hoa , Alkhateeb, Hassan B. , Hiwase, Devendra , Shah, Meera

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6309-6311

10.1182/blood-2022-164769 Get It

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome
Chhetri, Rakchha , Al‐Kali, Aref , Gangat, Naseema , Litzow, Mark R. , Begna, Kebede, Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Tefferi, Ayalew , Shah, Meera , Hahn, Christopher N , Tran, Elizabeth Ngoc Hoa , Singhal, Deepak , Hogan, William J. , Kutyna, Monika , Alkhateeb, Hassan B. , Baranwal, Anmol , Shanmuganathan, Naranie , Kumar, Sharad , THOMAS, DANIEL W. , Kok, Chung Hoow , Hiwase, Devendra

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6964-6965

10.1182/blood-2022-168349 Get It

Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
Tran, Diana , Rosta, Emily, Laidlaw, Alyshia , Rai, Manvir, Duran, Joana , Ammann, Eric M. , Fonseca, Rafaël

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 5212-5213

10.1182/blood-2022-165569 Get It

TMIC-58. PATTERNS OF CELLULAR SUBPOPULATION COHABITATION DEFINE GLIOBLASTOMA STATES
Bond, Kamila M. , Urcuyo, Javier , León, Gustavo De , Sereduk, Christopher, Singleton, Kyle , Langworthy, Jazlynn , Krishna, Chandan , Zimmerman, Richard S. , Patra, Devi Prasad, Smith, Kris A. , Donev, Kliment , Baxter, Leslie A., Mrugała, Maciej M. , Hu, Leland , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Curtin, Lee , Hawkins‐Daarud, Andrea , Leon, Gustavo De, Sereduk, Chris , Jackson, Pamela , Bendok, Bernard R. , Nakaji, Peter , Baxter, Leslie, Al‐Dalahmah, Osama , Tran, Nhan L. , Rubin, Joshua B

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii284-vii284

10.1093/neuonc/noac209.1102 Get It

Abstract Characterizing intra- and inter-tumoral heterogeneity of glioblastoma has historically relied on discrete classifications of malignant cell populations leaving immune and other cell populations, known to exist admixed with the malignant tumor cells, relatively neglected. Manifold learning algorithms can manage deconvolving multiple cell populations and are often used to track cell state transitions in single cell transcriptomics. We applied a manifold learning approach to TCGA microarray data (Nf525) and bulk transcriptomics of 134 image localized biopsies across 30 patients with primary and 9 with recurrent glioblastoma to further elucidate how to organize biopsies across a spectrum of possible tissue states. The algorithm revealed a low-dimensional manifold graph for which each biopsy lives across 3 polarizing tissue states - one that is associated with diffusely invaded brain, one that is enriched in mesenchymal genes, and one that is enriched in classical proliferative tumor signatures. We deconvolved the bulk transcriptomics of the image-localized biopsies to reveal the relative abundance of 18 malignant, immune, and other cell subpopulations in each biopsy. Overlaying the cellular decomposition onto the manifold graph visualizing the tissue state distributions revealed that transitions between states correlate with changes in cellular cohabitation composition. The tumor cellular cohabitation ecologies have the lowest diversity, as inferred by ecological measures such as Shannon entropy and evenness, at the distal poles of the graph when compared to the transitional arms. Further, we found that the relationship between imaging appearance of contrast enhancement on T1-weighted MRI and the biopsy cellular composition varies with sex and primary vs recurrent biopsy status. The limited spectrum of possible tissue states revealed by the manifold learning is suggestive of a limited continuum along which tumor and non-tumoral cell populations can cohabitate. Such a limited low-dimensional biological space may constrain the dynamics of tumor biology in a predictable manner.
CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL
Ashkan, Keyoumars, Campian, Jian , Trusheim, John, Tran, David , Anstass, George, Cobbs, Charles , Heth, Jason , Salacz, Michael, D’Andre, Stacy D. , Aiken, Robert, Moshel, Yaron A., Nam, Jooyeon, Pillainayagam, Clement, Wagner, Stephanie A., Walter, Kevin A. , Chaudary, Rekha, Goldlust, Samuel , Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin O. , Mikkelsen, Tom , Walbert, Tobias , Abram, Steve, Ewend, Matthew G., Khagi, Simon , Lovick, Darren, Kim, Lyndon, Loudon, William G. , Martinez, Nina , Thompson, Reid, Avigan, David , Fink, Karen, Geoffroy, Francois J., Giglio, Pierre , Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott , Nadji‐Ohl, Minou , Sanchin, Lhagva, Sloan, Andrew, Bosch, Marnix L. , Liau, Linda M. , Brem, Steven , IWAMOTO, FABIO MASSAITI , Tran, David D. , Lee, Ian , Bota, Daniela A. , Brenner, Andrew Jacob , Portnow, Jana , Lutzky, Jose , Meisel, Hans Jörg

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii66-vii66

10.1093/neuonc/noac209.259 Get It

Abstract BACKGROUND Standard of care (SOC) and patient survival in glioblastoma have changed little in the past 17 years. We evaluated in a phase 3 trial whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to SOC extends survival. Patients and METHODS Newly diagnosed glioblastoma patients were randomized 2:1 to either murcidencel or placebo. Under a crossover design, all patients could receive murcidencel following tumor recurrence. All parties remained blinded regarding treatments before recurrence. Patients thus received murcidencel at new diagnosis (nGBM) or at recurrence (rGBM) following crossover from placebo. The primary and secondary endpoints compare overall survival (OS) with contemporaneous, matched external controls. Four sets of analyses were conducted to ensure rigorous matching of the controls, reduce biases, and confirm the robustness of the results. RESULTS 331 patients were enrolled. With the crossover, 89% received murcidencel. Median OS (mOS) for nGBM patients (n = 232) was 19.3 months from randomization (22.4 months from surgery) with murcidencel vs. 16.5 months from randomization in the controls (HR = 0.80, p = 0.002). Survival at 48 months from randomization was 15.7% vs. 9.9%, and at 60 months was 13% vs. 5.7%. For rGBM (n = 64), mOS was 13.2 months from relapse vs. 7.8 months in the controls (HR = 0.58, p < 0.001). Survival at 24 months post-recurrence was 20.7% vs. 9.6%, and at 30 months post-recurrence was 11.1% vs 5.1%. In nGBM patients with methylated MGMT (n = 90), mOS was 30.2 months from randomization (33 months from surgery) with murcidencel vs. 21.3 months from randomization in the controls (HR = 0.74, p = 0.027). The treatment was well tolerated, with only 5 serious adverse events deemed at least possibly related to the vaccine. CONCLUSION Clinically meaningful and statistically significant survival extension was seen in both nGBM and rGBM patients treated with murcidencel and SOC compared with contemporaneous, matched external controls who received SOC alone.
NIMG-86. REVEALING THE BIOLOGY BEHIND MRI SIGNATURES IN GLIOBLASTOMA
Lewis, Erika , Swanson, Kristin R. , Hu, Leland , Swanson, Kristin R , Tran, Nhan L. , Plaisier, Christopher L.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii185-vii185

10.1093/neuonc/noac209.704 Get It

Abstract The brain is notoriously difficult to access because of its location and protective mechanisms, both internal and external. Imaging-based approaches, such as multiparametric magnetic resonance imaging (mpMRI), provide a method to bypass these obstacles. mpMRI can capture a wide range of data from tumors embedded in brain tissue through various imaging features. However, the biological function captured by each imaging feature remains largely unknown, particularly within the aggressive disease glioblastoma multiforme (GBM). We integrated our GBM SYstems Genetics Network AnaLysis (gbmSYGNAL) gene regulatory network (Plaisier, et al. 2016), based on the multi-omic patient data from The Cancer Genome Atlas (TCGA), with mpMRI-localized patient tumor biopsies. The gbmSYGNAL network was reconstructed within the new image-localized biopsies, and associations revealed a strong connection between the spoiled gradient recalled echo + contrast (SPGR+C) feature and the immune hallmarks of cancer. The SPGR+C method generates an image by employing a contrast agent that bypasses the blood brain barrier (BBB) through leaky blood vessels that have weakened from the force of the rapidly growing GBM tumor. Furthermore, a significant association between SPGR+C signal and the presence of both infiltrating macrophages and T cells indicated that peripheral immune cells may also cross the BBB at these leaky sites. Separately, the mean diffusivity (MD) & T2 features were linked to the sustained angiogenesis hallmark. These features displayed high association with angiogenic genes, such as FLT1, KDR, and PDGFRB, and correlated with the presence of histologically identified vessels. Detection of these disease-relevant functions via mpMRI features has powerful clinical applications, providing a non-invasive approach to GBM diagnosis, prognosis, and treatment direction.